Cryoport, Inc. (CYRX): Cost of Revenue
$93.12M
Year ended 2025-12-31
$98.68M
Trailing 12 months to 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.12M | +6.9% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $87.11M | -6.7% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $93.33M | n/c | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $133.40M | +5.9% | 2025-03-07, From 2022-01-01 |
| 2021-12-31 | $126.03M | +197.5% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $42.36M | +155.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $16.59M | +76.7% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $9.39M | +56.8% | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | $5.99M | +30.8% | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $4.58M | n/a | 2018-03-08, From 2016-01-01 |
| No annual figure between 2015-03-31 and 2016-12-31. | |||
| 2015-03-31 | $2.77M | +24.4% | 2016-06-28, From 2014-04-01 |
| 2014-03-31 | $2.22M | +40.0% | 2015-05-19, From 2013-04-01 |
| 2013-03-31 | $1.59M | +14.0% | 2014-06-25, From 2012-04-01 |
| 2012-03-31 | $1.39M | +6.9% | 2013-06-25, From 2011-04-01 |
| 2011-03-31 | $1.30M | n/a | 2012-06-27, From 2010-04-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | 2025-12-31 | $93.12M | +6.9% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $22.60M | +183.4% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $40.97M | -8.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $19.49M | +45.8% |
| Liquidia Corp (LQDA) | 2024-12-31 | $5.88M | +103.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $41.35M | +7.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $0 | -100.0% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $73.85M | +68.0% |
Compare CYRX, PHAT, LFVN, MRVI side by side · Screen every company in Pharmaceutical Preparations ↗